Biomarkers in COPD: Is Mortality the Holy Grail?

References

• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0. PubMed PMID: 23245604.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Amer J Respir Crit Care Med 2013; 187(4):347–365. doi: 10.1164/rccm.201204-0596PP. PubMed PMID: 22878278.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Loukides S, Gourgoulianis KI, Kostikas K. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med 2009; 103(5):650-60. doi: 10.1016/j.rmed.2009.01.001. PubMed PMID: 19167871.
   PubMed Web of Science ®Google Scholar
• Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Amer J Respir Crit Care Med 2011; 183(9):1129–1137. Epub 2010/12/21. doi: 10.1164/rccm.201009-1414PP. PubMed PMID: 21169466.
   PubMed Web of Science ®Google Scholar
• Kostikas K, Bakakos P, Papiris S, Stolz D, Celli BR. Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application? Curr Drug Targets 2013; 14(2):177–191. PubMed PMID: 23256717.
   PubMed Web of Science ®Google Scholar
• Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest 2012; 141(2):396–405. doi: 10.1378/chest.11-0495. PubMed PMID: 21835899.
   PubMed Web of Science ®Google Scholar
• Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax 2007; 62(8):657–660. doi: 10.1136/thx.2007.084228. PubMed PMID: 17687095; PubMed Central PMCID: PMC2117266.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed–urgently. Amer J Respir Crit Care Med 2010; 182(7):863–864. doi: 10.1164/rccm.201004-0602ED. PubMed PMID: 20884938.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Outcomes for COPD pharmacological trials: from lung function to biomarkers. Euro Respir J 2008; 31(2):416–469. doi: 10.1183/09031936.00099306. PubMed PMID: 18238951.
   PubMed Web of Science ®Google Scholar
• Holmgaard DB, Mygind LH, Titlestad I, Madsen H, Pedersen SS, Mortensen OH, Calprotectin—A marker of mortality in COPD? Results from a prospective cohort study. COPD 2013; 10(5):581–587. doi: 10.3109/15412555.2013.781580. PubMed PMID: 23844942.
   PubMedGoogle Scholar
• Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Digest Dis Sci 2011; 56(6):1601–1611. doi: 10.1007/s10620-010-1494-9. PubMed PMID: 21203903.
   PubMed Web of Science ®Google Scholar
• Garcia-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diag Ther 2013; 17(1):49–56. doi: 10.1007/s40291-013-0016-9. PubMed PMID: 23329363.
   PubMed Web of Science ®Google Scholar
• Cholidou KG, Kostakis ID, Manali ED, Perrea D, Margeli A, Vougas K, Calprotectin: a protein related to cardiovascular risk in adult patients with obstructive sleep apnea. Cytokine 2013; 61(3):917–923. doi: 10.1016/j.cyto.2012.12.014. PubMed PMID: 23375123.
   PubMed Web of Science ®Google Scholar
• Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Sputum proteomics in inflammatory and suppurative respiratory diseases. Amer J Respir Crit Care Med 2008; 178(5):444–452. doi: 10.1164/rccm.200703-409OC. PubMed PMID: 18565957; PubMed Central PMCID: PMC2643212.
   PubMed Web of Science ®Google Scholar
• Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan Hite R, Seeds MC, Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008; 102(4):567–573. doi: 10.1016/j.rmed.2007.11.011. PubMed PMID: 18164192; PubMed Central PMCID: PMC2347354.
   PubMed Web of Science ®Google Scholar
• Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013; 68(6):532–539. doi: 10.1136/thoraxjnl-2012-202538. PubMed PMID: 23396354.
   PubMed Web of Science ®Google Scholar
• Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscleros Thrombos Vasc Biol 2012; 32(2):223–229. doi: 10.1161/ATVBAHA.111.236927. PubMed PMID: 22095980; PubMed Central PMCID: PMC3262097.
   PubMed Web of Science ®Google Scholar
• Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation 2011; 123(11):1216–1226. doi: 10.1161/CIRCULATIONAHA.110.985523. PubMed PMID: 21382888; PubMed Central PMCID: PMC3072335.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Amer Heart J 2008; 155(1):49–55. doi: 10.1016/j.ahj.2007.08.018. PubMed PMID: 18082488; PubMed Central PMCID: PMC2645040.
   PubMed Web of Science ®Google Scholar
• Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, Calprotectin—A novel marker of obesity. PloS One 2009; 4(10):e7419. doi: 10.1371/journal.pone.0007419. PubMed PMID: 19823685; PubMed Central PMCID: PMC2758581.
   PubMed Web of Science ®Google Scholar
• Hirata A, Kishida K, Nakatsuji H, Hiuge-Shimizu A, Funahashi T, Shimomura I. High serum S100A8/A9 levels and high cardiovascular complication rate in type 2 diabetics with ultrasonographic low carotid plaque density. Diabetes Res Clin Pract 2012; 97(1):82–90. doi: 10.1016/j.diabres.2012.01.026. PubMed PMID: 22333479.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Euro Respir J 2008; 32(4):962–969. doi: 10.1183/09031936.00012408. PubMed PMID: 18579551.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Amer Coll Cardiol 2006; 47(12):2554–2560. doi: 10.1016/j.jacc.2006.04.039. PubMed PMID: 16781387.
   PubMed Web of Science ®Google Scholar
• Bartziokas K, Papaioannou AI, Minas M, Kostikas K, Banya W, Daniil ZD, Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulmon Pharmacol Therapeut 2011; 24(5):625–631. doi: 10.1016/j.pupt.2011.06.003. PubMed PMID: 21729761.
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2012; 185(10):1065–1072. doi: 10.1164/rccm.201110-1792OC. PubMed PMID: 22427534.
   PubMed Web of Science ®Google Scholar
• Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, Adrenomedullin refines mortality prediction by the BODE index in COPD—The “BODE-A” index. Euro Respir J 2013 doi: 10.1183/09031936.00058713. PubMed PMID: 23794469.
   Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67(11):957–963. doi: 10.1136/thoraxjnl-2011-201518. PubMed PMID: 22684094; PubMed Central PMCID: PMC3505864.
   Google Scholar
• Minas M, Mystridou P, Georgoulias P, Pournaras S, Kostikas K, Gourgoulianis KI. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD 2013; 10(1):28–34. doi: 10.3109/15412555.2012.727922. PubMed PMID: 23272665.
   PubMedGoogle Scholar
• Bartziokas K, Papaioannou AI, Loukides S, Papadopoulos A, Haniotou A, Papiris S, Serum uric acid on COPD exacerbation as predictor of mortality and future exacerbations. Euro Respir J 2013. doi: 10.1183/09031936.00209212. PubMed PMID: 23645404.
   Google Scholar